Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BMRN 
Biomarin Pharmaceutical Inc (BMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: BMRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $95.91
Year Target Price $95.91
| 16 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.98% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.58B USD | Price to earnings Ratio 20.43 | 1Y Target Price 95.91 |
Price to earnings Ratio 20.43 | 1Y Target Price 95.91 | ||
Volume (30-day avg) - | Beta 0.18 | 52 Weeks Range 52.93 - 94.85 | Updated Date 06/29/2025 |
52 Weeks Range 52.93 - 94.85 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.76% | Operating Margin (TTM) 30.05% |
Management Effectiveness
Return on Assets (TTM) 6.38% | Return on Equity (TTM) 9.64% |
Valuation
Trailing PE 20.43 | Forward PE 13.05 | Enterprise Value 9913722951 | Price to Sales(TTM) 3.59 |
Enterprise Value 9913722951 | Price to Sales(TTM) 3.59 | ||
Enterprise Value to Revenue 3.36 | Enterprise Value to EBITDA 12.76 | Shares Outstanding 191776000 | Shares Floating 179358191 |
Shares Outstanding 191776000 | Shares Floating 179358191 | ||
Percent Insiders 0.85 | Percent Institutions 98.97 |
Analyst Ratings
Rating 4.34 | Target Price 95.91 | Buy 7 | Strong Buy 16 |
Buy 7 | Strong Buy 16 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biomarin Pharmaceutical Inc
Company Overview
History and Background
BioMarin Pharmaceutical Inc. was founded in 1997 and is headquartered in San Rafael, California. It focuses on developing and commercializing therapies for serious and life-threatening rare genetic diseases. It has grown through internal development, acquisitions, and partnerships.
Core Business Areas
- Rare Genetic Diseases: Develops and commercializes therapies for patients with serious and life-threatening rare genetic diseases, primarily focusing on enzyme deficiencies, protein deficiencies, and other genetic disorders.
Leadership and Structure
The leadership team includes Alexander J. Denner as CEO, with a management team overseeing research, development, commercial operations, and finance. The organizational structure is typical of a biotechnology company, with divisions focused on specific therapeutic areas and functions.
Top Products and Market Share
Key Offerings
- Vimizim (elosulfase alfa): Vimizim is an enzyme replacement therapy for Morquio A syndrome (MPS IVA). While specific market share data is difficult to pinpoint, Vimizim holds a significant portion of the MPS IVA treatment market. Competitors are limited, as the market for MPS IVA treatments is niche. It has generated hundreds of millions in revenue annually.
- Naglazyme (galsulfase): Naglazyme is an enzyme replacement therapy for Mucopolysaccharidosis VI (MPS VI). Naglazyme holds a significant share of the MPS VI treatment market. Competitors are limited. It also generates hundreds of millions in revenue annually.
- Voxzogo (vosoritide): Voxzogo is a treatment for achondroplasia. Revenue is increasing significantly annually. Competitors include other treatments aimed at managing the complications of achondroplasia, but Voxzogo is the first to address the underlying cause directly. Competitors may include future gene therapies or other novel treatments.
- Kuvan (sapropterin dihydrochloride): Kuvan is a medication used to reduce phenylalanine levels in patients with phenylketonuria (PKU). Competitors include other dietary management approaches and Palynziq (pegvaliase). While once BioMarin's leading product, its revenues have declined due to generic competition.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long regulatory approval timelines, and significant competition. Focus is shifting to gene therapies and precision medicine.
Positioning
BioMarin is positioned as a leader in developing and commercializing therapies for rare genetic diseases. Its competitive advantage lies in its expertise in enzyme replacement therapies, gene therapies and its established infrastructure for developing and marketing rare disease treatments.
Total Addressable Market (TAM)
The total addressable market for rare genetic diseases is estimated to be very large, valued in the tens of billions of dollars. BioMarin is well-positioned to capture a significant share of this market, due to their product portfolio and development pipeline.
Upturn SWOT Analysis
Strengths
- Strong pipeline of rare disease therapies
- Expertise in enzyme replacement and gene therapies
- Established commercial infrastructure for rare disease products
- History of successful product launches
- Robust intellectual property portfolio
Weaknesses
- High dependency on a small number of products
- Risk associated with clinical trial outcomes
- High R&D costs
- Exposure to generic competition for established products
Opportunities
- Expansion into new rare disease markets
- Development of gene therapies for broader indications
- Acquisition of complementary technologies or product candidates
- Partnerships with other pharmaceutical companies
- Geographic expansion
Threats
- Competition from other biotechnology and pharmaceutical companies
- Regulatory hurdles and delays
- Pricing pressures from payers
- Patent challenges
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- RDHL
- SGEN
- ALNY
- REGN
Competitive Landscape
BioMarin holds a strong position in the rare disease market. Its competitive advantage lies in its expertise in enzyme replacement therapies and gene therapies. However, it faces competition from other biotechnology and pharmaceutical companies that are also developing therapies for rare diseases.
Major Acquisitions
Prosensa Holding N.V.
- Year: 2014
- Acquisition Price (USD millions): 840
- Strategic Rationale: To acquire drisapersen, a potential treatment for Duchenne muscular dystrophy (DMD).
Growth Trajectory and Initiatives
Historical Growth: BioMarin has experienced strong growth in revenue and product sales over the past decade, driven by the launch of new products and expansion into new markets.
Future Projections: Analysts predict continued growth in revenue and earnings, driven by the company's pipeline of new products and its focus on rare genetic diseases. Growth rates vary based on projections.
Recent Initiatives: Recent initiatives include the development of new gene therapies, the expansion of its commercial operations into new markets, and strategic acquisitions.
Summary
BioMarin is a strong player in the rare disease market, with a solid portfolio and pipeline. Its focus on enzyme replacement and gene therapies provides a competitive edge. It needs to manage R&D costs and pricing pressures. Competitors' activities and any potential regulatory changes will need to be closely monitored for risk mitigation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports (e.g., from Yahoo Finance, Bloomberg)
- Industry Reports (e.g., from EvaluatePharma, GlobalData)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomarin Pharmaceutical Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 1999-07-23 | President, CEO & Director Mr. Alexander Hardy | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3040 | Website https://www.biomarin.com |
Full time employees 3040 | Website https://www.biomarin.com | ||
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.